EP0381414A3 - Anti-ulcer composition - Google Patents

Anti-ulcer composition Download PDF

Info

Publication number
EP0381414A3
EP0381414A3 EP19900300897 EP90300897A EP0381414A3 EP 0381414 A3 EP0381414 A3 EP 0381414A3 EP 19900300897 EP19900300897 EP 19900300897 EP 90300897 A EP90300897 A EP 90300897A EP 0381414 A3 EP0381414 A3 EP 0381414A3
Authority
EP
European Patent Office
Prior art keywords
complex
ulcer
composition
ulcer composition
ulcers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19900300897
Other languages
German (de)
French (fr)
Other versions
EP0381414B1 (en
EP0381414A2 (en
Inventor
Richard J. Harwood
Luke T.H. Foo
Edward V. Henry
Jay L. Rheingold
Joseph S. Sonk
Robert C. Degroof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Publication of EP0381414A2 publication Critical patent/EP0381414A2/en
Publication of EP0381414A3 publication Critical patent/EP0381414A3/en
Application granted granted Critical
Publication of EP0381414B1 publication Critical patent/EP0381414B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C265/00—Derivatives of isocyanic acid
    • C07C265/14—Derivatives of isocyanic acid containing at least two isocyanate groups bound to the same carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

In accordance with the present invention a novel oral composition and method of using same for the treatment of ulcers and other gastrointestinal disorders is disclosed. The composition comprises an agent capable of forming an ulcer-adherent protective complex in an acid environment combined with one or more alkaline materials in a total amount sufficient to substantially prevent the formation of such a complex in the mouth and adherence of such a complex to the buccal mucosa.
EP90300897A 1989-01-30 1990-01-29 Anti-ulcer composition Expired - Lifetime EP0381414B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/303,871 US4975281A (en) 1989-01-30 1989-01-30 Anti-ulcer composition
US303871 1989-01-30

Publications (3)

Publication Number Publication Date
EP0381414A2 EP0381414A2 (en) 1990-08-08
EP0381414A3 true EP0381414A3 (en) 1991-08-07
EP0381414B1 EP0381414B1 (en) 1994-06-22

Family

ID=23174066

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90300897A Expired - Lifetime EP0381414B1 (en) 1989-01-30 1990-01-29 Anti-ulcer composition

Country Status (16)

Country Link
US (1) US4975281A (en)
EP (1) EP0381414B1 (en)
JP (1) JPH02270827A (en)
KR (1) KR900011464A (en)
AT (1) ATE107510T1 (en)
AU (1) AU626976B2 (en)
CA (1) CA2007334C (en)
DE (1) DE69010021T2 (en)
DK (1) DK0381414T3 (en)
ES (1) ES2055315T3 (en)
HU (1) HU203972B (en)
IE (1) IE64211B1 (en)
MY (1) MY105956A (en)
NZ (1) NZ232077A (en)
PT (1) PT92987B (en)
ZA (1) ZA90306B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196405A (en) * 1987-07-08 1993-03-23 Norman H. Oskman Compositions and methods of treating hemorrhoids and wounds
DE4022944A1 (en) * 1990-07-19 1992-01-23 Merck Patent Gmbh Tablets or dragees for chewing contg. sucralphate - contg. physiologically acceptable gel former e.g. xanthene gum and have pleasant taste and are of reasonable size
GB9025710D0 (en) * 1990-11-27 1991-01-09 Beecham Group Plc Novel treatment
US5164379A (en) * 1991-07-15 1992-11-17 Bristol-Myers Company Sucralfate/cyclodextrin complexes
DE4139883A1 (en) * 1991-11-29 1993-06-03 Michael Prof Dr Dittgen Prodn. of bio-adhesive medicament, e.g. oral or vaginal tablet - comprises mixing drug with swellable, bio-adhesive polymer, dispersant and opt. binder
US5447918A (en) * 1992-07-27 1995-09-05 Mccullough; Ricky W. Gastrointestinal anti-irritant composition comprising sucralfate and methods of use
DK66493D0 (en) * 1993-06-08 1993-06-08 Ferring A S PREPARATIONS FOR USE IN TREATMENT OF INFLAMMATORY GAS DISORDERS OR TO IMPROVE IMPROVED HEALTH
JPH09501678A (en) * 1993-08-13 1997-02-18 ベイヤー、コーポレーション Hydrolyzed gelatin as an aroma enhancer for chewable tablets.
US6028190A (en) 1994-02-01 2000-02-22 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
WO1997030988A1 (en) * 1996-02-21 1997-08-28 Toa Eiyo Ltd. Cycloalkanopyridine derivatives, process for producing the same, and peptic ulcer remedy comprising the same
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
AU2001270304A1 (en) 2000-07-07 2002-01-21 The Administrators Of The Tulane Educational Fund Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
US6887926B1 (en) 2001-11-16 2005-05-03 Oatey Co. Bonding compositions for chlorinated polymers and methods of using the same
DE102004042139B4 (en) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Peroral dosage forms to achieve a retarding effect after drug intake with a meal
TWI445540B (en) * 2007-04-20 2014-07-21 Ajinomoto Kk Anti-hypothermia composition
LU91351B1 (en) * 2007-08-08 2009-02-09 Recipe Holding S A Bio-magnum chew, tablet
GR1008308B (en) 2013-05-31 2014-10-02 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Local pharmaceutical and medi-tech compositions containing combinations of sucralfat, hyaluronic acid, arginine and one natural moistening factor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107209A1 (en) * 1982-10-27 1984-05-02 Chugai Seiyaku Kabushiki Kaisha Sucralfate preparation
EP0136100A2 (en) * 1983-09-02 1985-04-03 Marion Merrell Dow Inc. Sucralfate suspension for use in treating ulcers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3432489A (en) * 1965-11-05 1969-03-11 Chugai Pharmaceutical Co Ltd Disaccharide polysulfate aluminium compound and method
US4676984A (en) * 1985-08-14 1987-06-30 American Home Products Corp. Rehydratable antacid composition
DK164199C (en) * 1986-05-16 1992-10-19 Chugai Pharmaceutical Co Ltd SUCRALPHATE PREPARATION FOR USE ON OESOPHAGUS MUCOSA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107209A1 (en) * 1982-10-27 1984-05-02 Chugai Seiyaku Kabushiki Kaisha Sucralfate preparation
EP0136100A2 (en) * 1983-09-02 1985-04-03 Marion Merrell Dow Inc. Sucralfate suspension for use in treating ulcers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biological abstract nb: 85061174 STAHLBERG M. et al: " Adsorption of bile acids by sucralfate antacids and cholestyramine in-vi & CLIN.THER.9(6), 1987, 615-621. *
Medline abstract nb: 84287225 MOCKEL W. et al: " Changes in the transmural electric potential difference in the region of stomach ulcer. Local effect of sucralfate, aluminium hydroxyde and magnesium trisilicate& FORTSCHR.MED. jul 12, 1984, 102 (25-26),p 70912. *
Medline abstract Nb: 89392138 BORELLA L.E. et al: " Cytoprotective and antiulcer activities of the antacid magaldrate in the & ARZNEIMITTELFORSCHUNG jul. 1989, 39 (7) p 786-9. *

Also Published As

Publication number Publication date
CA2007334A1 (en) 1990-07-30
PT92987A (en) 1990-07-31
AU626976B2 (en) 1992-08-13
IE900314L (en) 1990-07-30
CA2007334C (en) 1999-08-31
US4975281A (en) 1990-12-04
MY105956A (en) 1995-02-28
EP0381414B1 (en) 1994-06-22
AU4859290A (en) 1990-08-02
DE69010021T2 (en) 1994-10-06
DE69010021D1 (en) 1994-07-28
ZA90306B (en) 1990-10-31
JPH02270827A (en) 1990-11-05
HU203972B (en) 1991-11-28
KR900011464A (en) 1990-08-01
DK0381414T3 (en) 1994-08-22
PT92987B (en) 1995-11-30
ES2055315T3 (en) 1994-08-16
HU9000379D0 (en) 1990-03-28
EP0381414A2 (en) 1990-08-08
HUT53812A (en) 1990-12-28
IE64211B1 (en) 1995-07-26
NZ232077A (en) 1991-10-25
ATE107510T1 (en) 1994-07-15

Similar Documents

Publication Publication Date Title
AU626976B2 (en) Anti-ulcer composition
AU1857888A (en) Reduced base-content chewing gum compositions having anesthetic properties
AU1857988A (en) Anesthetic-containing chewing gum compositions
AU628817B2 (en) Tartar inhibiting oral composition and method
AU596161B2 (en) Oral hygiene compositions
CY2575B1 (en) Improved denture adhesive composition
AU6863687A (en) Oral compositions containing fluoride, strontium and polyacrylic acid polymers
AU1748688A (en) Heterogeneous chewing gum composition and method of preparation
AU579601B2 (en) Multi-layered chewing gum composition having different rates of flavor release
AU7291787A (en) Chewing gum composition and method of making same
ES8802204A1 (en) A solid oral anticariogenic composition.
AU7402587A (en) Oral compositions
IT1215332B (en) PHARMACEUTICAL COMPOSITION CONTAINING SULGLICOTIDE FOR THERAPY OF GASTRIC ULCER
AU8117087A (en) Chewing gum compositions having sequential acid release
CA2177961A1 (en) Use of dimeticone for treating aphthae and stomatitis
AU2204388A (en) Oral magnesium and potassium compositions and use
AU1900488A (en) Device and composition for treatment of gums
AU588971B2 (en) Antacid chewing gum
ZA867494B (en) Antiinflammatory compositions and methods
AU7054587A (en) Oral hygiene compositions
IL70990A0 (en) Pharmaceutical compositions containing glyceryl mononitrates
AU7087287A (en) Process and composition for oral hygiene
CA2183764A1 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19901219

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920813

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 107510

Country of ref document: AT

Date of ref document: 19940715

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69010021

Country of ref document: DE

Date of ref document: 19940728

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2055315

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

ITF It: translation for a ep patent filed

Owner name: MODIANO & ASSOCIATI S.R.L.

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3013296

EAL Se: european patent in force in sweden

Ref document number: 90300897.7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20090113

Year of fee payment: 20

Ref country code: ES

Payment date: 20090218

Year of fee payment: 20

Ref country code: LU

Payment date: 20090129

Year of fee payment: 20

Ref country code: DK

Payment date: 20090113

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20090104

Year of fee payment: 20

Ref country code: DE

Payment date: 20090123

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20090126

Year of fee payment: 20

Ref country code: GB

Payment date: 20090128

Year of fee payment: 20

Ref country code: GR

Payment date: 20081215

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090119

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20090127

Year of fee payment: 20

Ref country code: SE

Payment date: 20090108

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20090113

Year of fee payment: 20

BE20 Be: patent expired

Owner name: E.R. *SQUIBB & SONS INC.

Effective date: 20100129

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20100128

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20100130

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20100129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100129